• Explore /
  • Poster
  • / Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

Phase 1b/2 trial of ribociclib+binimetinib in metastatic NRAS-mutant melanoma: Safety, efficacy, and recommended phase 2 dose (RP2D).

Abstract Poster

Authors

Martin Schuler

Martin H. Schuler

West German Cancer Center, University Hospital, Essen, Germany

Martin H. Schuler , Paolo A. Ascierto , Filip Yves Francine Leon De Vos , Michael Andrew Postow , Carla M.L.- Van Herpen , Matteo S. Carlino , Jeffrey A. Sosman , Carola Berking , Georgina V. Long , Amy Weise , Ralf Gutzmer , Martin Kaatz , Grant A. McArthur , Gary Schwartz , Adil Daud , Kati Maharry , Padmaja Yerramilli-Rao , Lisa Zimmer , Viviana Bozon , Rodabe Navroze Amaria

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT01781572

Citation

J Clin Oncol 35, 2017 (suppl; abstr 9519)

DOI

10.1200/JCO.2017.35.15_suppl.9519

Abstract #

9519

Poster Bd #

127

Abstract Disclosures

Similar Posters

First Author: Qing Zhou

First Author: Asim Amin

First Author: Gregory J. Riely

First Author: Zeynep Eroglu